News

Positive Outcomes for Bexicaserin in 12-Month Study by Lundbeck

Positive Outcomes for Bexicaserin in 12-Month Study by Lundbeck

Exciting Developments from Lundbeck on Bexicaserin

H. Lundbeck A/S has recently shared some encouraging findings regarding their investigational drug, bexicaserin, which was evaluated in a 12-month open-label extension of the PACIFIC trial. This trial included participants aged between 12 and 65 who are affected by Developmental and Epileptic Encephalopathies (DEEs). The results show that bexicaserin achieved a median seizure reduction of 59.3% in countable motor seizures over the extension period, indicating a meaningful impact on the quality of life for these individuals.

Safety and Tolerability of Bexicaserin

Furthermore, the treatment was found to be safe and well-tolerated, with most participants completing the full 12-month period. As Johan Luthman, EVP and Head of Research & Development at Lundbeck, remarked, the study's outcomes bolster confidence in bexicaserin's unique profile and its potential to meet the significant unmet needs of patients suffering from DEEs.

PACIFIC Study Insights

The PACIFIC open-label extension (OLE) study involved a diverse group of participants, including those diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEEs. The 52-week OLE study aimed to explore not just the safety and tolerability of multiple doses of bexicaserin, but also analyze how effectively it reduces the frequency of seizures. Results are expected to be shared at a medical conference in the near future, promising to shed further light on bexicaserin's efficacy.

Diving Deeper into Efficacy Results

When we look at the figures, the participants who transitioned from a placebo group to bexicaserin treatment saw a 58.2% decrease in motor seizures, while those who were continuously treated with bexicaserin during the PACIFIC trial experienced a reduction of 60.4%. These statistics paint a hopeful picture for patients dealing with such challenging conditions.

Understanding the Safety Profile

Throughout the 12-month OLE, participation remained high with 92.7% of participants continuing until the end of the study. The overall safety profile was favorable with upper respiratory tract infections being the most common treatment emergent adverse events reported in more than 5% of patients. Other reported effects included seizures and decreased appetite, yet these did not deter the overall positivity surrounding the treatment.

About Bexicaserin and the PACIFIC Trial

Bexicaserin, also known as LP352, is a 5-HT2C receptor superagonist that is currently part of a global Phase III clinical program aimed at providing new therapeutic options for patients aged two years and older. The compound has been granted Breakthrough Therapy Designation by the FDA for its potential in treating DEEs. This underscores the promising nature of bexicaserin as a revolutionary approach in neurology.

As part of the PACIFIC study, which was previously conducted across various locations, including the United States and Australia, participants underwent thorough evaluation while receiving treatment. Notably, the trial's design included a detailed consideration of participants' safety and the drug's pharmacokinetics, ensuring robust data collection throughout the study.

The Vision of H. Lundbeck A/S

Lundbeck is firmly dedicated to improving brain health, an endeavor beautifully articulated in their mission. With decades of expertise in neuroscience, the company remains focused on addressing complex neurological disorders that affect countless individuals globally. Their innovative spirit drives them to explore new frontiers in treatment, aiming to deliver solutions where none exist.

Frequently Asked Questions

What is the PACIFIC trial?

The PACIFIC trial is a Phase 1b/2a double-blind, placebo-controlled trial designed to assess the safety, tolerability, and efficacy of bexicaserin in participants with Developmental and Epileptic Encephalopathies.

How effective is bexicaserin according to the latest study?

The recent study indicated a median reduction of 59.3% in countable motor seizures over a 12-month treatment period with bexicaserin, showcasing its effectiveness.

What are the most common side effects noted during the study?

Common side effects included upper respiratory tract infections, seizures, decreased appetite, and heavy fatigue, but overall, the safety profile was deemed favorable.

Who can participate in the PACIFIC trial?

Participants aged 12 to 65 with diagnoses of Developmental and Epileptic Encephalopathies are eligible for the PACIFIC trial.

What is Lundbeck's commitment to brain health?

Lundbeck aims to improve lives affected by neurological and psychiatric diseases through innovative treatments and research focused on understanding brain biology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 360

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 251

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 41

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 120

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 95

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 229

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 79

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Growth Ahead for Luxury Apparel Market Forecast

Updated Category News Views 132

Luxury Apparel Market Set for Significant Growth The global luxury apparel market is poised for substantial growth, projected to expand by USD 25.2 billion in the upcoming years, specifically from 2025 to 2029. This growth trajectory is largely attributed to increasing disposable income in emerging economies, where luxury sportswear is becoming increasingly popular. With...

Continue Reading
Food Emulsifiers Market Set for Significant Growth

Updated Category News Views 175

Market Potential: Scratching the Surface Who would have thought that a tiny ingredient like food emulsifiers would hold such massive sway in the food industry? Well, here we are, peering into a future where the global food emulsifiers market could skyrocket to a whopping USD 5.07 billion by 2035. That's right, these unsung heroes of the food world are shaking things up,...

Continue Reading
RBC Capital Highlights Challenges for Permanent TSB Stock

Updated Category News Views 79

RBC Capital's Cautious Stance on Permanent TSB Group Holdings Recently, RBC Capital has taken a critical look at Permanent TSB Group Holdings PLC and has initiated coverage with an Underperform rating and a price target set at €1.00. This decision has raised eyebrows amongst investors and analysts alike, as it indicates significant concerns regarding the bank's...

Continue Reading
Revolutionizing Equine Insurance with AI Technology Today

Updated Category News Views 208

Innovating Equine Insurance with AI Solutions Halo AI, the pioneering platform for equine performance prediction and insurance, is redefining risk management within the equine industry. Unveiling its groundbreaking offerings, Halo integrates predictive analytics with flexible insurance cover, paving the way for a revolutionary approach to ensuring horses' welfare and...

Continue Reading
Insights on Managerial Trading Activities in Columbus A/S

Updated Category News Views 197

Understanding Recent Managerial Trading at Columbus A/S Columbus A/S, a company that specializes in providing technology and consultancy services, has recently made significant disclosures as per regulatory requirements. The firm is dedicated to transparency, especially in instances where trading activities involve managerial roles. This commitment to openness fosters...

Continue Reading